Dr. Golant discusses the role of disease severity in her selection of atopic dermatitis treatments, particularly noting the characterization of hand and foot involved patients as often moderate cases, and highlighting the rapid response observed in these areas when treated.
Saakshi Khattri, MD, and Mark Lebwohl, MD, provide insight on the significance of steroid-free treatment options for the management of pediatric patients with plaque psoriasis and address unique considerations and challenges treating patients with skin of color.
Expert dermatologists highlight the use of nonsteroidal topical therapies, roflumilast and tapinarof, for the management of plaque psoriasis.
Brad Glick, DO, MPH, says it is essential to consider patient lifestyles when choosing atopic dermatitis therapies.
Brad Glick, DO, MPH, emphasizes the importance of personalized and inclusive communication in choosing therapeutics for atopic dermatitis.
Brian Kim, MD, underscores the critical gap in addressing severe itch in atopic dermatitis, often overshadowed by the visible manifestations of skin rash.
Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.
Christopher Bunick, MD, PhD, expands on how clinicians can personalize treatment plans for each patient.
Christopher Bunick, MD, PhD, reviews benchmarks for optimal outcomes in patients with atopic dermatitis and compares treatments available.
A dermatology expert reviews the role of barrier function in AD and outlines available treatments, emphasizing the importance of moisturizing and rapid options when appropriate, as well as the efficacy of rapid systemic treatments in patients when appropriate.
Alexandra Golant, MD, delves into the prevalence and profound influence of hand and foot involvement in her patients, shedding light on the significant burden it imposes on their quality of life.
Mark Lebwohl, MD, and Saakshi Khattri, MD, examine the use of spesolimab in various diseases, including generalized pustular psoriasis (GPP), and comment on the use and safety of deucravacitinib.
Drs Mark Lebwohl and Saakshi Khattri review the significance of long-term data of bimekizumab for plaque psoriasis management.
Raj Chovatiya, MD, PhD, dissects the nomenclature of atopic dermatitis and shares the importance of understanding other conditions under the eczema umbrella.
Raj Chovatiya, MD, PhD, gives an overview of what all clinicians need to know about the updated atopic dermatitis guidelines published by the American Academy of Dermatology including approaches with systemic therapies, which therapeutic modalities to prioritize, and patient considerations to guide decision-making.
Experts in dermatology discuss the use of bimekizumab in clinical practice for plaque psoriasis as well as its off-label use.
Saakshi Khattri, MD, and Mark Lebwohl, MD, share key insights on recent biologic, topical, and oral treatment approvals for the management of plaque psoriasis.
Peter Lio, MD, explains the importance of having a wide-range of solutions and how he incorporates alternative approaches alongside conventional medicine.
Peter Lio, MD, expands on dosing considerations to treat atopic dermatitis with involvement on the hands and feet for different ages, weights, lifestyles, and more.
Peter Lio, MD, takes a deep dive into the results of the 3 LIBERTY-AD-HAFT study and how it impacts the treatment of hand-foot atopic dermatitis.
Susan Taylor, MD, explained the current state of diversity in clinical trials, what is going well, and opportunities to improve.
Susan Taylor, MD, shared what she wants to know about patients' functionality to treat their atopic dermatitis with hand or foot involvement.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the tolerability and low discontinuation rates of tapinarof for patients in AD clinical trials, as well as discuss the adverse events associated with the drug.
Adelaide A. Hebert, MD, FAAD, shares insight on the eczema area and severity index 75 (EASI75) results from the ADORING 1 and ADORING 2 clinical trials for use of tapinarof in AD.
Expert dermatologists review the validated investigator global assessment for AD (vIGA-AD) response in the ADORING 1 and ADORING 2 trials for tapinarof.
An expert in dermatology reviews the case of a 33-year-old male patient suffering from atopic dermatitis for the past 3 years. He breaks down the panel's conversation on the use of non-steroidal topicals and emphasizes how patient assistance programs can ease burden for patients and providers.
Shawn Kwatra, MD, presents a case involving a 73-year-old African American female seeking treatment for her atopic dermatitis. In this segment Dr Kwatra explains the panels thoughts and rationale behind the prescribed treatments, discussing how each option works and its limitations.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the rapid itch reduction results found in the clinical trials for tapinarof in AD, as well as primary end points of the studies.
Expert dermatologists highlight the patient characteristics in the ADORING 1 and ADORING 2 trials, both focusing on tapinarof for the treatment of AD.
